<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02299947</url>
  </required_header>
  <id_info>
    <org_study_id>NL45370.100.14</org_study_id>
    <nct_id>NCT02299947</nct_id>
  </id_info>
  <brief_title>Bloodtranfusions After Aortic Surgery</brief_title>
  <acronym>FIBTEG</acronym>
  <official_title>Comparison of a Single Dose Fibrinogen With Placebo and the Number of Blood Transfusions After Ascending Aorta Surgery (FIBTEG Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Antonius Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St. Antonius Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to answer the following question: Leads a primary coagulation
      corrected with a single dose of fibrinogen concentrate after ascending aorta-arc
      reconstruction to a decrease in the number of allogenic blood transfusions, compared to
      placebo?
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cardiothoracic surgery (CTC) is associated with blood loss and an increased risk for impaired
      coagulation by the use of a CBP. Coagulation is a process of primary hemostasis by adhesion
      of trombocytes and aggregation, followed by secondary coagulation and fibrin formation.
      During CTC fibrinogen is the first coagulation factor which reaches critical concentration
      necessary for clotting. Point of Care clotting assay with thromboelastography (TEG) provides
      qualitative information on coagulation factors and clot strength. Specific coagulation factor
      correction of impaired clotting improves clot strength and may reduces the number of
      perioperative allogeneic blood transfusions, resulting in possible reduction of postoperative
      blood loss and reduction of the risk of re-operation in the short and long term. The
      hypothesis of this study is that a single dose fibrinogen concentrate immediately after CTC
      leads to a decrease in the number of allogenic blood transfusions in patients with clinically
      impaired clotting, verified by TEG.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2014</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of transfused blood products</measure>
    <time_frame>24 hours after surgery</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood loss</measure>
    <time_frame>24 hours after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Re-operation</measure>
    <time_frame>30 day after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>30 day mortality</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">82</enrollment>
  <condition>Hemorrhage</condition>
  <condition>Thoracic Aneurysm</condition>
  <arm_group>
    <arm_group_label>Haemocomplettan P</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Study patients that receive Haemocomplettan P</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NaCl 0.9%</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Study patients that receive NaCl 0.9%</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Haemocomplettan P</intervention_name>
    <arm_group_label>Haemocomplettan P</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>NaCl 0.9%</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Elective surgery for thoracic aneurysm

        Exclusion Criteria:

          -  Prior trombosis or myocardial infarction, congenital coagulation disorder, use of
             anti-coagulants prior to surgery, prior thoracic surgery, pregnancy, pre-operative
             fibrinogen concentration &lt;1g/L
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Noordzij, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Antonius Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eline Vlot</last_name>
    <email>e.vlot@antoniusziekenhuis.nl</email>
  </overall_contact>
  <location>
    <facility>
      <name>St Antonius hospital</name>
      <address>
        <city>Nieuwegein</city>
        <state>Utrecht</state>
        <zip>3435 CM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Peter Noordzij, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 18, 2014</study_first_submitted>
  <study_first_submitted_qc>November 20, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 24, 2014</study_first_posted>
  <last_update_submitted>March 4, 2018</last_update_submitted>
  <last_update_submitted_qc>March 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>St. Antonius Hospital</investigator_affiliation>
    <investigator_full_name>dr. P. Noordzij</investigator_full_name>
    <investigator_title>MD PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Aneurysm</mesh_term>
    <mesh_term>Aortic Aneurysm, Thoracic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

